The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

Lymphoma, B Cell Clinical Trial

Official title:
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma

Status Completed

Clinical Trial Summary

Multiple ascending dose study to evaluate safety/tolerability, pharmacokinetic and pharmacodynamics effects of KA2237 (PI3 Kinase p110β/δ Inhibitor) in patients with B Cell Lymphoma and determine the maximum tolerated dose (MTD) in Part I of the study. In Part II, patients with B cell lymphoma will be treated with KA2237 at the MTD to evaluate safety and efficacy in the patient population.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02679196
Study type	Interventional
Source	Karus Therapeutics Limited
Contact
Status	Completed
Phase	Phase 1
Start date	July 2016
Completion date	December 24, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00210379` - Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma	Phase 2
Terminated	`NCT00523939` - DepoCyt for Active Lymphomatous or Leukemic Meningitis	Phase 2
Completed	`NCT00210314` - Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma	Phase 2
Not yet recruiting	`NCT02992834` - Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma	Phase 4
Withdrawn	`NCT00210340` - A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis	Phase 1